Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for COX2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Recombinant Protein (Wild-Type) | COX2 Recombinant Protein, full-length or catalytic domain. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. | View COX2 Products |
| Recombinant Protein (Mutant Panel) | COX2 Variant Proteins (R120A, Y355F, etc.) for selectivity and resistance mechanism studies. Theoretical MW verified. | View COX2 Products |
| Gene Delivery | COX2 Premade Lentivirus Particles, full-length ORF. For stable cell line construction with native glycosylation and endoplasmic reticulum localization. | View COX2 Products |
| Validator | COX2 siRNA Set (3 unique duplexes) for knockdown verification and assay specificity confirmation. | View COX2 Products |
| Research Benchmark / Control Antibody | Anti-COX2 Recombinant Antibody (Research Grade) for Western blot, IHC, and ELISA validation. Recombinant positive control for assay standardization. | View COX2 Products |
| Counter-Screen Target | COX1 (PTGS1) Recombinant Protein. HEK293 expressed, sequence verified, native folding. Essential for selectivity profiling and safety assessment. | View COX1 Products |
| Pathway Partner 1 | mPGES-1 (PTGES) Recombinant Protein. Downstream prostaglandin E2 synthase; synergistic dual-target screening opportunity. | View PTGES Products |
| Pathway Partner 2 | EP4 (PTGER4) Recombinant Protein. Prostaglandin E2 receptor; druggable parallel signaling node for immunomodulation in oncology. | View PTGER4 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (COX1 vs COX2) | Matched human COX1 and COX2 ortholog proteins, both >95% purity, HEK293 expressed for native conformation. Sequence verified. |
| Cross-species Preclinical Evaluation | Human, Mouse, and Cynomolgus COX2 ortholog proteins available; theoretical MW confirmed. |
| Cellular Target Engagement & Conformation | COX2 Lentivirus stable cell line system preserves endoplasmic reticulum localization and native glycosylation for PGE2 release assays. |
| Assay Specificity & False Positives | COX2 siRNA included for target-specific knockdown and off-target control. Validated siRNA pools for biological specificity checks. |
| Enzymatic Activity Standardization | Sequence-verified WT and catalytic mutants (e.g., active site variants R120A, Y355F) for assay validation and mechanism of action studies. |
| Benchmark Controls | Recombinant anti-COX2 biosimilar antibody included for assay standardization and reproducibility. |
Live COX2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The COX2 inhibitor landscape has evolved significantly following the withdrawal of early coxibs (rofecoxib, valdecoxib) due to cardiovascular safety concerns. Current R&D focuses on "third-generation" selective COX2 inhibitors with improved CV safety profiles, and novel applications in cancer chemoprevention (particularly colorectal and breast cancer). The market is shifting toward combination therapies targeting the prostaglandin pathway at multiple nodes (COX2 + mPGES-1) to achieve superior efficacy with reduced dosages. In parallel, the integration of COX2 inhibitors with immune checkpoint blockades is emerging as a key strategy to reverse immunosuppression in solid tumors, especially in colorectal cancer and non-small cell lung cancer. The next wave of R&D also includes topical NSAIDs to avoid systemic CV risk, dual inhibitors (COX2 + 5-LOX or mPGES-1), and novel modalities such as PROTACs for targeted COX2 degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective COX2 Inhibitor) | Pfizer (Celecoxib), Merck (Etoricoxib), generics | Osteoarthritis, Chronic Pain, FAP | COX1/COX2 Selectivity Ratio (Need pure ortholog pair) |
| Dual Inhibitor (COX2 + 5-LOX / mPGES-1) | Licofelone developers, Daewoong | Anti-inflammatory (Improved GI safety) | Enzymatic Panel Screening (Need WT + Mutant COX2, plus 5-LOX or mPGES-1) |
| Topical NSAID | Grünenthal, Horizon Therapeutics | Localized Pain (Avoid systemic CV risk) | Cell-based Penetration Assays (Need Lentivirus-stable keratinocyte lines) |
| Cancer Chemoprevention | NCI trials, Aspirin/COX2 combinations | Colorectal Adenoma, Breast Cancer | Long-term Cell Culture Models (Need stable COX2-expressing lines) |
| PROTACs / Degraders | Emerging Biotech | Inflammation, Cancer | Degradation kinetics (Need reliable benchmark Abs for Western Blot and stable cell lines) |
EGF-like Domain and Key Genetic Variants
Beyond the protein interaction and assay needs, PTGS2 (COX2) contains an EGF-like domain (UniProt P35354) that may influence protein-protein interactions and signaling. Additionally, several missense variants have been identified, including rs3218622, rs4648279, and rs5272 (dbSNP, recorded as VAR_016262, VAR_016263, VAR_011980 in UniProt). These variants are important for understanding individual drug response and resistance mechanisms, particularly in long-term chemoprevention and oncology settings.